-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎Editor of WuXi AppTec content team
Nested's third project, NEST-3, targets an as-yet-unnamed transcription factor, which, according to Dr.
Klaus Hoeflich, co-founder and CEO of Nested, occurs in 5 percent of all cancers
.
After analyzing this protein, Nested found that a "pocket triggered by mutations" could serve as a target for
drug development.
Nested's technology expanded the patient population that could benefit from the drug to 10-12%.
Nested Therapeutics today announced the completion of a $90 million Series A funding round, which will advance Nested's total funding to $125 million to help develop
its next generation of precision medicine drugs for cancer.
Notably, one of Nested's co-founders, Dr.
Kevan Shokat, whose team published a groundbreaking paper in the leading scientific journal Nature in 2013, pointed out how to target the KRAS mutation
that was considered indogutable at the time.
The paper ultimately paves the way for Amgen to develop Lumakras (sotorasib) targeting the KRAS mutation, a drug approved by the FDA last year to treat lung cancer patients
with KRAS G12C mutations.
Nested's platform consists of three major projects: mapping mutant populations to corresponding structural proteomes, identifying drug-making "pockets" and their cancer-driving mechanisms, and designing innovative drugs optimized for drug-making "pockets
.
" Nested's main project, NEST-1, is a non-degrading, bimolecular gel that targets many components of the pro-divigen-activated protein kinase (MAPK) pathway and demonstrates potential for superior efficacy, tolerability, and central nervous system (CNS) activity
in a single- or combination drug format in many RAS/MAPK-driven models 。 NEST-1 acts like the literal meaning of glue, although it does not lead to the degradation of the target protein, but by connecting the molecules in the pathway with other molecules, the activation of the information pathway can not be completed, and then achieve the purpose of
inhibiting disease progression.
Nested's third project, NEST-3, targets an as-yet-unnamed transcription factor, which, according to Dr.
Klaus Hoeflich, co-founder and CEO of Nested, occurs in 5 percent of all cancers
.
After analyzing this protein, Nested found that a "pocket triggered by mutations" could serve as a target for
drug development.
Nested's technology expanded the patient population that could benefit from the drug to 10-12%.
The funding Nested receives will enable the company to advance its R&D programs, attract more talent, and further develop its cancer-driven mutation platform to expand the field of
precision medicine.
"Our drug development platform allows us to have a high degree of confidence in identifying those new, often overlooked, non-traditional target 'pockets' while gaining enough information to design therapeutic drugs that perfectly match them with innovative mechanisms," said Mr.
Darrin Miles, CEO of Nested.
Best-in-class' precision cancer therapies benefit a larger patient population
.
”
WuXi AppTec provides integrated, end-to-end new drug development and manufacturing services to the global biopharmaceutical industry, covering the fields
of chemical drug development and production, biological research, preclinical testing and clinical trial development, cell and gene therapy development, testing and production.
If you have relevant business needs, please click on the picture below to fill in the specific information
.
